Versartis, Inc. (VSAR) Stake Raised by Northern Trust Corp

Northern Trust Corp lifted its position in shares of Versartis, Inc. (NASDAQ:VSAR) by 15.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 420,553 shares of the biopharmaceutical company’s stock after buying an additional 56,761 shares during the quarter. Northern Trust Corp owned about 1.19% of Versartis worth $7,339,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. First Quadrant L P CA acquired a new stake in shares of Versartis during the second quarter worth $155,000. Bank of America Corp DE increased its position in shares of Versartis by 46.3% during the first quarter. Bank of America Corp DE now owns 9,482 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 3,001 shares during the period. UBS Group AG acquired a new stake in shares of Versartis during the first quarter worth $367,000. American International Group Inc. increased its position in shares of Versartis by 20.7% during the first quarter. American International Group Inc. now owns 18,962 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 3,250 shares during the period. Finally, Wellington Management Group LLP acquired a new stake in shares of Versartis during the first quarter worth $408,000. Institutional investors own 73.99% of the company’s stock.

In other news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of Versartis stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $3.29, for a total transaction of $7,007,700.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 2,132,769 shares of company stock valued at $7,014,761 over the last quarter. Corporate insiders own 10.90% of the company’s stock.

Versartis, Inc. (NASDAQ VSAR) opened at $1.77 on Friday. Versartis, Inc. has a twelve month low of $1.60 and a twelve month high of $24.00. The company has a current ratio of 2.39, a quick ratio of 2.39 and a debt-to-equity ratio of 0.09.

Versartis (NASDAQ:VSAR) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.78). During the same quarter in the previous year, the business posted ($0.92) EPS. sell-side analysts expect that Versartis, Inc. will post -4.14 earnings per share for the current fiscal year.

Several equities research analysts have recently weighed in on VSAR shares. BidaskClub cut shares of Versartis from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. Cantor Fitzgerald set a $34.00 price objective on shares of Versartis and gave the stock a “buy” rating in a research report on Thursday, July 27th. Canaccord Genuity set a $28.00 price target on shares of Versartis and gave the stock a “buy” rating in a report on Friday, July 28th. Zacks Investment Research cut shares of Versartis from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Finally, ValuEngine cut shares of Versartis from a “hold” rating to a “sell” rating in a report on Thursday, August 17th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $7.22.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.chaffeybreeze.com/2017/11/12/versartis-inc-vsar-stake-raised-by-northern-trust-corp.html.

Versartis Company Profile

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Want to see what other hedge funds are holding VSAR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Versartis, Inc. (NASDAQ:VSAR).

Institutional Ownership by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply